(Boursier.com) — Abbott reported strong fiscal second quarter sales of $10 billion supported by core business performance. Adjusted earnings per share were $1.08. The consensus was $1.05 adjusted EPS for $9.7 billion in sales. Annual adjusted profit is still expected to be between $4.3 and $4.5, but reflects higher expectations for the base business, as well as lower forecasts for sales of covid tests. Abbott now expects full-year 2023 organic sales growth, excluding Covid-19 testing sales, to be in the ‘low double digits’, while Covid-19 testing sales are expected to be around $1.3 billion.
©2023 Boursier.com